Latest Protein Sciences Corporation Stories
Ready to Manufacture a Vaccine for the H7N9 Influenza Virus MERIDEN, Conn., May 2, 2013 /PRNewswire/ -- Protein Sciences announced today that it had completed development of the vector required to manufacture a vaccine to protect against the new and deadly H7N9 Bird Flu and is prepared to commence manufacturing within a few days of receiving orders for the vaccine. It has been possible to move quickly and safely to develop the H7N9 vaccine because we use modern, proprietary,...
MERIDEN, Conn., Feb. 20, 2013 /PRNewswire/ -- Protein Sciences Corporation announced today that Wayne Hachey, DO (Colonel, U.S. Army, ret.) has joined the Company's management as Head, Government and Clinical Affairs. Dr. Hachey is a physician who has dedicated 28 years of service to the military healthcare system, including six years as a subject matter expert advising senior Department of Defense (DoD) leadership regarding the DoD's vaccine policy. He was also responsible for...
PEARL RIVER, N.Y., Feb. 15, 2013 /PRNewswire/ -- At a press conference today showcasing Protein Sciences' newly leased manufacturing facility for Flublok, the Company announced that the Biomedical Advanced Research and Development Authority (BARDA), a division of the U.S. Department of Health and Human Services, will continue to support the Company's influenza vaccines program. BARDA held an internal review of the Protein Sciences program and made a decision to modify its contract...
MERIDEN, Conn., Jan. 16, 2013 /PRNewswire/ -- The U.S. FDA approved Flublok for people 18-49 years old - making it the first recombinant vaccine for influenza available on the market. Approval for all people 18 years and above is expected later in 2013. Flublok features: First influenza vaccine made without the use of live influenza virus First egg-free influenza vaccine Highly purified without preservatives (thimerosal), antibiotics or adjuvants Three times the active...
MERIDEN, Conn., Oct. 24, 2012 /PRNewswire/ -- Protein Sciences announced that Tim Fields, Vice President of Quality, was named recipient of the Ken Chapman Industry Recognition Award during the International Validation Week Conference presented by the Institute of Validation Technology (IVT) on Oct. 23, 2012. Ken Chapman who died of pancreatic cancer in 2006 was renowned for his forward-thinking approach to regulatory issues and best practices. Many of his ideas have become...
MERIDEN, Conn., Sept. 10, 2012 /PRNewswire/ -- Protein Sciences Corporation announced that this afternoon there will be a presentation of clinical data for the pandemic (monovalent) formulation of Protein Sciences innovative solution for protection from influenza, FluBlok, by John Treanor, MD, Chief of the Infectious Diseases Division of the Department of Medicine at the University of Rochester Medical Center. The presentation will occur at the Interscience Conference on...
AMSTERDAM, The Netherlands, June 18, 2012 /PRNewswire/ -- uniQure, a leader in the field of human gene therapy, announced today the extension of its collaboration with Protein Sciences Corporation ("Protein Sciences") for the exclusive use of Protein Sciences' expresSF+(R) (SF+) insect cell line in uniQure's AAV gene therapy programs for three specific disease indications. uniQure has the option to extend this exclusivity further into additional indications in the future....
MERIDEN, Conn., April 30, 2012 /PRNewswire/ -- Protein Sciences Corporation has expanded its senior management team by adding leaders in the areas of manufacturing and finance. The additions come at a time of great anticipation as the Company prepares for the launch of its first product, FluBlok®, a first-in-class recombinant vaccine for seasonal influenza. Mireli Fino joins us as VP, Manufacturing Operations. She comes from Wyeth (now Pfizer) where she spent the past 20 years in...
MERIDEN, Conn., Feb. 22, 2012 /PRNewswire/ -- Protein Sciences Corporation ("Protein Sciences") announced today that it has granted Merck, through a subsidiary, a non-exclusive license to Protein Sciences' proprietary expresSF+® serum-free insect cell line (SF+) and related technology (collectively, PS Technology) to conduct vaccine research. In addition, Protein Sciences has granted Merck an exclusive license to use PS Technology for commercial production of an undisclosed vaccine...
MERIDEN, Conn., Nov. 9, 2010 /PRNewswire/ -- Protein Sciences Corporation (PSC) announced that it has expanded its 2006 agreement with UMN Pharma, Inc. (UMN), to which it licensed exclusive rights to commercialize FluBlok® and PanBlok® (together "PSC's influenza vaccines") in the Japan market. The amendment allows UMN to enter into collaboration agreements with Astellas Pharma Inc. (Astellas) and IHI Corporation (IHI). Astellas' role will be to support further development, licensure...
